CN101802188B - 用于因子Xa抑制剂的解毒剂和其使用方法 - Google Patents

用于因子Xa抑制剂的解毒剂和其使用方法 Download PDF

Info

Publication number
CN101802188B
CN101802188B CN2008801079738A CN200880107973A CN101802188B CN 101802188 B CN101802188 B CN 101802188B CN 2008801079738 A CN2008801079738 A CN 2008801079738A CN 200880107973 A CN200880107973 A CN 200880107973A CN 101802188 B CN101802188 B CN 101802188B
Authority
CN
China
Prior art keywords
fxa
antibody
toxinicide
polypeptide
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801079738A
Other languages
English (en)
Chinese (zh)
Other versions
CN101802188A (zh
Inventor
卢根民
戴维·R·菲利普斯
帕特里克·安德烈
乌马·辛哈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN101802188A publication Critical patent/CN101802188A/zh
Application granted granted Critical
Publication of CN101802188B publication Critical patent/CN101802188B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN2008801079738A 2007-09-28 2008-09-26 用于因子Xa抑制剂的解毒剂和其使用方法 Active CN101802188B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97634307P 2007-09-28 2007-09-28
US60/976,343 2007-09-28
US9057408P 2008-08-20 2008-08-20
US61/090,574 2008-08-20
PCT/US2008/078014 WO2009042962A2 (en) 2007-09-28 2008-09-26 Antidotes for factor xa inhibitors and methods of using the same

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201310301566.3A Division CN103446579B (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法
CN201110447251.0A Division CN102559644B (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法
CN2011104472050A Division CN102533702A (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法

Publications (2)

Publication Number Publication Date
CN101802188A CN101802188A (zh) 2010-08-11
CN101802188B true CN101802188B (zh) 2013-08-21

Family

ID=40481812

Family Applications (4)

Application Number Title Priority Date Filing Date
CN2008801079738A Active CN101802188B (zh) 2007-09-28 2008-09-26 用于因子Xa抑制剂的解毒剂和其使用方法
CN2011104472050A Pending CN102533702A (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法
CN201110447251.0A Active CN102559644B (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法
CN201310301566.3A Active CN103446579B (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN2011104472050A Pending CN102533702A (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法
CN201110447251.0A Active CN102559644B (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法
CN201310301566.3A Active CN103446579B (zh) 2007-09-28 2008-09-26 用于因子xa抑制剂的解毒剂和其使用方法

Country Status (26)

Country Link
US (8) US8153590B2 (enExample)
EP (4) EP2193196B1 (enExample)
JP (7) JP5637561B2 (enExample)
KR (4) KR102069498B1 (enExample)
CN (4) CN101802188B (enExample)
AU (7) AU2008304192B9 (enExample)
BR (2) BRPI0816837B1 (enExample)
CA (1) CA2697583C (enExample)
CY (3) CY1118482T1 (enExample)
DK (3) DK3078743T3 (enExample)
ES (3) ES2796623T3 (enExample)
FR (1) FR20C1045I2 (enExample)
HR (2) HRP20161255T1 (enExample)
HU (4) HUE031647T2 (enExample)
IL (4) IL203993A (enExample)
LT (3) LT2193196T (enExample)
MX (1) MX2010003095A (enExample)
NL (1) NL301063I2 (enExample)
NO (2) NO2019040I1 (enExample)
NZ (1) NZ583944A (enExample)
PL (3) PL3078743T3 (enExample)
PT (3) PT3078743T (enExample)
SG (1) SG185263A1 (enExample)
SI (3) SI3078743T1 (enExample)
WO (1) WO2009042962A2 (enExample)
ZA (2) ZA201002039B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
PT3078743T (pt) * 2007-09-28 2020-07-15 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
JP5739816B2 (ja) * 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
EP3604510B1 (en) 2009-03-30 2025-03-26 Alexion Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
WO2011008885A1 (en) * 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
EP2316931B1 (de) 2009-10-30 2016-12-28 Senova Gesellschaft für Biowissenschaft und Technik mbH Polymergekoppelte Peptidasen
WO2011075602A1 (en) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
JP5796872B2 (ja) * 2009-12-17 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の結晶性塩
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
TW201240664A (en) * 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
US20140050743A1 (en) 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
FR2972114B1 (fr) * 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
PH12013501924A1 (en) 2011-03-30 2017-10-25 Boehringer Ingelheim Int Anticoagulant antidotes
EP2760887B1 (en) 2011-09-30 2024-10-23 The Children's Hospital of Philadelphia Compositions and methods for modulating hemostasis
WO2013082210A1 (en) * 2011-11-29 2013-06-06 Perosphere Inc. Anticoagulant reversal agents
US20130230901A1 (en) * 2012-02-14 2013-09-05 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
WO2013123248A1 (en) 2012-02-16 2013-08-22 Portola Pharmaceuticals, Inc. MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
SI2827883T1 (sl) 2012-03-21 2019-08-30 Baxalta GmbH Inhibitorji TFPI in postopki uporabe
CA2876361C (en) * 2012-06-14 2020-06-30 Portola Pharmaceuticals, Inc. Method for purification of recombinant factor xa derivatives
AU2013293573B2 (en) * 2012-07-25 2016-10-27 Catalyst Biosciences, Inc. Modified Factor X polypeptides and uses thereof
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
FR3000895B1 (fr) * 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
FR3007410B1 (fr) * 2013-06-21 2016-05-27 Lab Francais Du Fractionnement Facteur x depourvu de domaine gla
KR101988705B1 (ko) 2013-09-24 2019-06-12 화이자 인코포레이티드 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물
JP6629744B2 (ja) * 2013-11-01 2020-01-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 第Ｘａ因子の半減期を延ばす組成物および方法
WO2015183085A1 (en) 2014-05-26 2015-12-03 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
ES2907190T3 (es) * 2014-07-31 2022-04-22 Haemonetics Corp Detección de la reversión de un anticoagulante mediante pruebas de coagulación por ecarina y factor Xa
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
AU2015305413B2 (en) * 2014-08-20 2020-09-24 Alexion Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
CN105030703B (zh) * 2015-06-23 2018-03-23 上海旭东海普药业有限公司 一种防治疗栓塞性疾病的利伐沙班片及其制备方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
ES2884119T3 (es) 2016-02-24 2021-12-10 Alexion Pharma Inc Fórmulas liofilizadas para antídoto contra el factor Xa
US10640822B2 (en) 2016-02-29 2020-05-05 Iridia, Inc. Systems and methods for writing, reading, and controlling data stored in a polymer
US10859562B2 (en) 2016-02-29 2020-12-08 Iridia, Inc. Methods, compositions, and devices for information storage
RU2022101599A (ru) * 2016-02-29 2022-02-25 Айридия, Инк. Способы, композиции и устройства для хранения информации
US10438662B2 (en) 2016-02-29 2019-10-08 Iridia, Inc. Methods, compositions, and devices for information storage
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3472314B1 (en) 2016-06-17 2021-05-05 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives
WO2018115235A1 (en) 2016-12-22 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antidotes to anti-coagulant drugs allowing diagnosis and treatment
AU2017383232B2 (en) 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN111246821A (zh) * 2017-08-21 2020-06-05 美国绿阳生物技术及医药公司 光吸收组合物和使用方法
CN118745229A (zh) 2017-11-15 2024-10-08 诺和诺德股份有限公司 增强fx活化的因子x结合物
US12195774B2 (en) 2018-06-19 2025-01-14 Alexion Pharmaceuticals, Inc. Antidotes to factor XA inhibitors
CN112261935A (zh) * 2018-08-14 2021-01-22 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
JP7641903B2 (ja) * 2019-02-07 2025-03-07 アレクシオン ファーマシューティカルズ， インコーポレイテッド 頭蓋内出血の治療方法及び効果の評価方法
US11655465B1 (en) 2019-05-02 2023-05-23 Iridia, Inc. Enzymes and systems for synthesizing DNA
DK4010379T3 (da) * 2019-08-08 2025-06-30 Alexion Pharma Inc Sammensætninger og fremgangsmåder til fremstilling af faktor Xa og derivater
WO2021257356A1 (en) * 2020-06-16 2021-12-23 Alexion Pharmaceuticals, Inc. Methods for testing andexanet potency
US11837302B1 (en) 2020-08-07 2023-12-05 Iridia, Inc. Systems and methods for writing and reading data stored in a polymer using nano-channels
ES3020087T3 (en) 2020-09-21 2025-05-21 Instr Laboratory Co Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample
CN113484386B (zh) * 2021-05-21 2024-02-13 郑州轻工业大学 一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116327627B (zh) * 2023-03-10 2024-06-07 四川大学 一种四面体框架核酸-光甘草定复合物及其在皮肤美白方面的用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH596313A5 (enExample) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
WO1986005803A1 (fr) 1985-03-30 1986-10-09 Marc Ballivet Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993006126A1 (en) 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
WO1993018782A1 (en) 1992-03-20 1993-09-30 Cor Therapeutics, Inc. Glycosylation-mediated inhibition of factor x
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv) * 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A modified coagulation agent
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
WO1998039456A1 (en) * 1997-03-07 1998-09-11 Washington University Factor x variant
JPH1149800A (ja) * 1997-06-05 1999-02-23 Fujimori Kogyo Kk アンヒドロトロンビンの合成方法
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
WO2000054787A1 (en) * 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6858599B2 (en) 1999-06-30 2005-02-22 Mochida Pharmaceutical Co., Ltd. Tricyclic compound having spiro union
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1095933A1 (en) * 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
CA2401778C (en) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
WO2001068605A1 (en) * 2000-03-13 2001-09-20 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US20030064414A1 (en) * 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
US7138506B2 (en) 2001-05-09 2006-11-21 Genetic Id, Na, Inc. Universal microarray system
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US20040198660A1 (en) * 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en) * 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
JP2007527539A (ja) 2004-03-05 2007-09-27 ザ スクリプス リサーチ インスティテュート ハイスループットグリカンマイクロアレイ
JP4441336B2 (ja) 2004-06-11 2010-03-31 日本碍子株式会社 マイクロアレイの製造方法
US9223929B2 (en) 2005-03-14 2015-12-29 The California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
WO2006102687A1 (en) 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
PT1948608E (pt) 2005-11-08 2012-05-24 Millennium Pharm Inc Novos sais farmacêuticos e polimorfos de um inibidor do fator xa
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
PT3078743T (pt) * 2007-09-28 2020-07-15 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
US8455439B2 (en) * 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
US8436144B2 (en) 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
EP3604510B1 (en) * 2009-03-30 2025-03-26 Alexion Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
WO2011008885A1 (en) 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same

Also Published As

Publication number Publication date
HRP20161255T1 (hr) 2016-12-02
JP5637561B2 (ja) 2014-12-10
CN102559644A (zh) 2012-07-11
CY1118482T1 (el) 2017-07-12
JP2018100290A (ja) 2018-06-28
BR122022001846B1 (pt) 2022-12-27
AU2014210620B2 (en) 2016-05-12
BRPI0816837B1 (pt) 2022-10-18
US20240082367A1 (en) 2024-03-14
US8455441B2 (en) 2013-06-04
US9062298B2 (en) 2015-06-23
FR20C1045I2 (fr) 2021-08-27
CN103446579A (zh) 2013-12-18
ES2849426T3 (es) 2021-08-18
JP6047127B2 (ja) 2016-12-21
MX2010003095A (es) 2010-04-09
LT2193196T (lt) 2016-12-12
NL301063I2 (nl) 2021-06-23
KR102069498B1 (ko) 2020-01-23
LTPA2020540I1 (lt) 2021-01-11
US20200276280A1 (en) 2020-09-03
IL264886B (en) 2020-03-31
PT3078743T (pt) 2020-07-15
ZA201002039B (en) 2015-11-25
US20140044773A1 (en) 2014-02-13
SG185263A1 (en) 2012-11-29
AU2014210620A1 (en) 2014-08-28
HK1210443A1 (en) 2016-04-22
KR20170100071A (ko) 2017-09-01
EP2193196B1 (en) 2016-07-13
US9388401B2 (en) 2016-07-12
PT2915564T (pt) 2021-02-09
DK2193196T3 (en) 2016-11-07
JP2020109113A (ja) 2020-07-16
SI2915564T1 (sl) 2021-03-31
CA2697583A1 (en) 2009-04-02
US8153590B2 (en) 2012-04-10
US20090098119A1 (en) 2009-04-16
US20150057228A1 (en) 2015-02-26
JP2017043632A (ja) 2017-03-02
HUE031647T2 (en) 2017-07-28
JP6300885B2 (ja) 2018-03-28
ES2796623T3 (es) 2020-11-27
AU2021218033A1 (en) 2021-09-09
NO2019040I1 (no) 2019-11-08
CN101802188A (zh) 2010-08-11
JP2010539945A (ja) 2010-12-24
IL272926A (en) 2020-04-30
ZA201406514B (en) 2016-10-26
IL203993A (en) 2017-11-30
KR20100077172A (ko) 2010-07-07
WO2009042962A2 (en) 2009-04-02
ES2597436T3 (es) 2017-01-18
NO2020033I1 (no) 2020-09-23
PT2193196T (pt) 2016-10-24
EP2915564B1 (en) 2020-11-04
KR20160025038A (ko) 2016-03-07
BRPI0816837A2 (pt) 2020-08-18
WO2009042962A9 (en) 2009-09-11
HUE052423T2 (hu) 2021-04-28
DK2915564T3 (da) 2021-02-08
US8889129B2 (en) 2014-11-18
AU2013205326A8 (en) 2013-06-06
HRP20201071T1 (hr) 2020-10-30
PL3078743T3 (pl) 2020-11-02
EP3824902A1 (en) 2021-05-26
US20120269788A1 (en) 2012-10-25
DK3078743T3 (da) 2020-08-10
HUS2000057I1 (hu) 2021-01-28
CA2697583C (en) 2016-04-12
NL301063I1 (enExample) 2020-09-16
PL2193196T3 (pl) 2017-07-31
CY1123504T1 (el) 2021-06-25
CY2020042I2 (el) 2021-06-25
AU2008304192A1 (en) 2009-04-02
AU2013205326A1 (en) 2013-05-09
CN102533702A (zh) 2012-07-04
EP2915564A1 (en) 2015-09-09
EP2193196A2 (en) 2010-06-09
PL2915564T3 (pl) 2021-07-19
JP2022153574A (ja) 2022-10-12
AU2024287094A1 (en) 2025-01-16
FR20C1045I1 (enExample) 2020-10-30
EP3078743A1 (en) 2016-10-12
LTC3078743I2 (lt) 2022-06-10
KR101698214B1 (ko) 2017-01-20
NZ583944A (en) 2012-06-29
CN102559644B (zh) 2015-03-25
CY2020042I1 (el) 2021-06-25
KR20200009131A (ko) 2020-01-29
KR102271404B1 (ko) 2021-07-02
IL203993A0 (en) 2011-07-31
US11839646B2 (en) 2023-12-12
IL255397A0 (en) 2017-12-31
US20160354449A1 (en) 2016-12-08
WO2009042962A3 (en) 2009-06-04
IL255397B (en) 2019-03-31
AU2008304192B2 (en) 2014-05-15
LT3078743T (lt) 2020-09-25
SI2193196T1 (sl) 2017-01-31
CN103446579B (zh) 2015-04-22
SI3078743T1 (sl) 2020-08-31
AU2008304192A2 (en) 2010-04-08
AU2017200212A1 (en) 2017-02-02
US20140079684A1 (en) 2014-03-20
JP2014218521A (ja) 2014-11-20
AU2019204123A1 (en) 2019-07-04
HUE050063T2 (hu) 2020-11-30
JP2025063249A (ja) 2025-04-15
AU2008304192B9 (en) 2024-02-01
US10675335B2 (en) 2020-06-09
EP3078743B1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
CN101802188B (zh) 用于因子Xa抑制剂的解毒剂和其使用方法
EP3604510B1 (en) Antidotes for factor xa inhibitors and methods of using the same
EP2453910B1 (en) Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
HK40052336A (en) Antidotes for factor xa inhibitors and methods of using the same
HK40022611A (en) Antidotes for factor xa inhibitors and methods of using the same
HK1229844A1 (en) Antidotes for factor xa inhibitors and methods of using the same
HK1229844B (en) Antidotes for factor xa inhibitors and methods of using the same
HK1236989A1 (en) Antidotes for factor xa inhibitors and methods of using the same
HK1210443B (en) Antidotes for factor xa inhibitors and methods of using the same
HK1143398B (en) Antidotes for factor xa inhibitors and methods of using the same
HK1167346B (en) Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant